Distinct Synaptic Vesicle Proteomic Signatures Associated with Pre- and Post-Natal Oxycodone-Exposure.
in utero
oxycodone
post-natal
proteomics
rodent model
synaptic vesicles
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
25 05 2022
25 05 2022
Historique:
received:
19
03
2022
revised:
21
05
2022
accepted:
22
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
The current opioid crisis, which has ravaged all segments of society, continues to pose a rising public health concern. Importantly, dependency on prescription opioids such as oxycodone (oxy) during and after pregnancy can significantly impact the overall brain development of the exposed offspring, especially at the synapse. A significant knowledge gap that remains is identifying distinct synaptic signatures associated with these exposed offspring. Accordingly, the overall goal of this current study was to identify distinct synaptic vesicle (SV) proteins as signatures for offspring exposed to oxy in utero (IUO) and postnatally (PNO). Using a preclinical animal model that imitates oxycodone exposure in utero (IUO) and postnatally (PNO), we used a quantitative mass spectrometry-based proteomics platform to examine changes in the synaptic vesicle proteome on post-natal day 14 (P14) IUO and PNO offspring. We identified MEGF8, associated with carpenter syndrome, to be downregulated in the IUO offspring while LAMTOR4, associated with the regulator complex involved in lysosomal signaling and trafficking, was found to be upregulated in the PNO groups, respectively. Their respective differential expression was further validated by Western blot. In summary, our current study shows exposure to oxy in utero and postnatally can impact the SV proteome in the exposed offspring and the identification of these distinct SV signatures could further pave the way to further elucidate their downstream mechanisms including developing them as potential therapeutic targets.
Identifiants
pubmed: 35681434
pii: cells11111740
doi: 10.3390/cells11111740
pmc: PMC9179517
pii:
doi:
Substances chimiques
Guanine Nucleotide Exchange Factors
0
LAMTOR4 protein, human
0
MEGF8 protein, human
0
Membrane Proteins
0
Proteome
0
Oxycodone
CD35PMG570
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Cell Rep. 2016 Jan 26;14(3):547-559
pubmed: 26774477
J Pharmacol Exp Ther. 2002 Jan;300(1):26-33
pubmed: 11752093
Transl Psychiatry. 2020 Sep 23;10(1):329
pubmed: 32968044
Nat Protoc. 2013 May;8(5):998-1009
pubmed: 23619891
PLoS One. 2011;6(10):e25535
pubmed: 22043286
Am J Obstet Gynecol. 2008 Jan;198(1):126.e1-4
pubmed: 18166326
JHEP Rep. 2019 Jul 09;1(3):240-255
pubmed: 32039374
Clin Drug Investig. 2017 Dec;37(12):1191-1201
pubmed: 29098567
Brain Behav Immun. 2020 Feb;84:45-58
pubmed: 31765790
AJNR Am J Neuroradiol. 2019 Dec;40(12):2161-2165
pubmed: 31624119
Bioinformatics. 2009 Apr 15;25(8):1091-3
pubmed: 19237447
J Pharmacol Exp Ther. 2006 Aug;318(2):461-8
pubmed: 16644901
Curr Neuropharmacol. 2017 Nov 14;15(8):1156-1173
pubmed: 28474563
Yakugaku Zasshi. 2015;135(5):697-702
pubmed: 25948304
J Proteome Res. 2007 Jun;6(6):2239-47
pubmed: 17444669
J Neurochem. 2007 Jun;101(6):1448-62
pubmed: 17355250
J Biosci. 2005 Mar;30(2):245-52
pubmed: 15886461
J Mass Spectrom. 2005 Feb;40(2):169-75
pubmed: 15706614
Elife. 2013 Sep 17;2:e01160
pubmed: 24052814
Front Neuroendocrinol. 2018 Oct;51:1-13
pubmed: 28965857
Trends Neurosci. 2010 Jun;33(6):267-76
pubmed: 20207024
Neuropsychopharmacology. 2014 Jan;39(1):88-103
pubmed: 24045585
Mol Pain. 2015 May 30;11:32
pubmed: 26024835
Iran J Public Health. 2019 Dec;48(12):2154-2164
pubmed: 31993383
Neurology. 2017 Feb 28;88(9):909-915
pubmed: 28148631
Drug Metab Dispos. 2008 Oct;36(10):2005-13
pubmed: 18606742
Hippocampus. 2006;16(6):521-30
pubmed: 16598705
Mol Cell Proteomics. 2007 Jan;6(1):29-42
pubmed: 17028301
FEBS Lett. 2020 Jan;594(1):31-42
pubmed: 31423582
Science. 2017 Oct 20;358(6361):377-381
pubmed: 28935770
Mol Cell Proteomics. 2016 Feb;15(2):368-81
pubmed: 26307175
Neuropharmacology. 2004;47 Suppl 1:33-46
pubmed: 15464124
N Engl J Med. 2016 Mar 31;374(13):1253-63
pubmed: 27028915
Int J Mol Sci. 2017 Jan 22;18(1):
pubmed: 28117754
Early Hum Dev. 2019 Oct 29;140:104910
pubmed: 31675665
Cells. 2019 Dec 19;9(1):
pubmed: 31861723
Neurotoxicol Teratol. 2015 Mar-Apr;48:69-77
pubmed: 25683798
Am J Hum Genet. 2012 Nov 2;91(5):897-905
pubmed: 23063620
BMC Neurosci. 2018 Mar 23;19(1):15
pubmed: 29571287
J Perinat Med. 1990;18(4):305-12
pubmed: 2262875
Neurosci Bull. 2018 Oct;34(5):854-858
pubmed: 29786759
Int J Mol Med. 2011 Dec;28(6):1077-85
pubmed: 21874227
Pediatr Neurol. 2012 Jul;47(1):1-6
pubmed: 22704008
Front Cell Dev Biol. 2021 Jan 07;8:619199
pubmed: 33490084
Glob J Health Sci. 2014 Sep 18;6(7 Spec No):83-91
pubmed: 25363183
J Neurosci Res. 2010 Nov 15;88(15):3215-21
pubmed: 20734417